Vitiligo and Graves' disease following treatment of malignant melanoma with recombinant human interleukin 4

被引：4
作者：
Weiss, GR
Fehrenkamp, SH
Tokaz, LK
Sunderland, MC
机构：
[1] AUSTIN ENDOCRINE ASSOCIATES,AUSTIN,TX
[2] CENT TEXAS ONCOL ASSOCIATES,AUSTIN,TX
[3] DALLAS HEMATOL & ONCOL ASSOCIATES,DALLAS,TX
来源：
DERMATOLOGY | 1996年 / 192卷 / 03期
关键词：
Graves' disease; vitiligo; malignant melanoma; interleukin; 4; recombinant human;
D O I：
10.1159/000246387
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
This report describes a patient with metastatic malignant melanoma treated with recombinant human interleukin 4 who developed vitiligo and severe Graves' Disease after therapy, The patient has experienced complete remission of melanoma for 49+ months. The association of antitumor response, vitiligo and thyroid disorders is reviewed.
引用
收藏
页码：283 / 285
页数：3
相关论文
共 22 条
  • [1] HYPOTHYROIDISM AFTER TREATMENT WITH INTERLEUKIN-2 AND LYMPHOKINE-ACTIVATED KILLER CELLS
    ATKINS, MB
    MIER, JW
    PARKINSON, DR
    GOULD, JA
    BERKMAN, EM
    KAPLAN, MM
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1988, 318 (24) : 1557 - 1563
  • [2] AUTOANTIBODIES TO NUCLEAR MITOTIC APPARATUS IN A PATIENT WITH VITILIGO AND AUTOIMMUNE-THYROIDITIS
    AUERGRUMBACH, P
    STANGL, M
    [J]. DERMATOLOGY, 1993, 186 (03) : 229 - 231
  • [3] THE CAUSES OF AUTOIMMUNE THYROID-DISEASE
    DEGROOT, LJ
    QUINTANS, J
    [J]. ENDOCRINE REVIEWS, 1989, 10 (04) : 537 - 562
  • [4] PROLONGED SURVIVAL IN METASTATIC MALIGNANT-MELANOMA ASSOCIATED WITH VITILIGO
    DUHRA, P
    ILCHYSHYN, A
    [J]. CLINICAL AND EXPERIMENTAL DERMATOLOGY, 1991, 16 (04) : 303 - 305
  • [5] A PHASE-II STUDY OF INTERLEUKIN-2 AND LYMPHOKINE-ACTIVATED KILLER CELLS IN PATIENTS WITH METASTATIC MALIGNANT-MELANOMA
    DUTCHER, JP
    CREEKMORE, S
    WEISS, GR
    MARGOLIN, K
    MARKOWITZ, AB
    ROPER, M
    PARKINSON, D
    CIOBANU, N
    FISHER, RI
    BOLDT, DH
    DOROSHOW, JH
    RAYNER, AA
    HAWKINS, M
    ATKINS, M
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (04) : 477 - 485
  • [6] FISHMAN P, 1993, CANCER, V72, P2365, DOI 10.1002/1097-0142(19931015)72:8<2365::AID-CNCR2820720812>3.0.CO
  • [7] 2-G
  • [8] HEGEDUS L, 1994, ACTA DERM-VENEREOL, V74, P120
  • [9] HOON DSB, 1991, CANCER RES, V51, P2002
  • [10] THYROID-FUNCTION ABNORMALITIES ASSOCIATED WITH THE CHRONIC OUTPATIENT ADMINISTRATION OF RECOMBINANT INTERLEUKIN-2 AND RECOMBINANT INTERFERON-ALPHA
    JACOBS, EL
    CLARESALZLER, MJ
    CHOPRA, IJ
    FIGLIN, RA
    [J]. JOURNAL OF IMMUNOTHERAPY, 1991, 10 (06) : 448 - 455
123